Equities research analysts expect Integer Holdings Corp (NYSE:ITGR) to announce $312.95 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Integer’s earnings. The lowest sales estimate is $311.60 million and the highest is $314.30 million. Integer reported sales of $305.09 million during the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The firm is scheduled to issue its next quarterly earnings results before the market opens on Thursday, October 31st.
On average, analysts expect that Integer will report full-year sales of $1.27 billion for the current financial year. For the next year, analysts expect that the firm will post sales of $1.33 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Integer.
Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. Integer had a net margin of 15.73% and a return on equity of 13.31%. The firm had revenue of $314.20 million for the quarter, compared to analyst estimates of $318.50 million. During the same quarter in the prior year, the firm earned $1.06 EPS. The company’s revenue was down .1% on a year-over-year basis.
NYSE:ITGR traded up $1.73 during mid-day trading on Friday, reaching $75.01. 11,292 shares of the company were exchanged, compared to its average volume of 255,595. Integer has a 12 month low of $67.72 and a 12 month high of $92.61. The company has a fifty day moving average of $75.12 and a 200 day moving average of $76.89. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.78. The stock has a market cap of $2.39 billion, a PE ratio of 19.84 and a beta of 1.05.
In other news, Director Jean M. Hobby sold 6,000 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $80.19, for a total value of $481,140.00. Following the transaction, the director now owns 15,475 shares of the company’s stock, valued at approximately $1,240,940.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.24% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its stake in shares of Integer by 68.2% in the 2nd quarter. SG Americas Securities LLC now owns 3,844 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 1,559 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Integer by 41.2% in the 2nd quarter. Prudential Financial Inc. now owns 434,777 shares of the medical equipment provider’s stock valued at $36,487,000 after purchasing an additional 126,819 shares during the last quarter. Aviva PLC bought a new position in shares of Integer in the 2nd quarter valued at about $967,000. UBS Asset Management Americas Inc. boosted its stake in shares of Integer by 2.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 33,322 shares of the medical equipment provider’s stock valued at $2,796,000 after purchasing an additional 937 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Integer by 6.3% in the 2nd quarter. Northern Trust Corp now owns 854,642 shares of the medical equipment provider’s stock valued at $71,723,000 after purchasing an additional 51,001 shares during the last quarter. 98.53% of the stock is currently owned by institutional investors.
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.